

10 May 2022

The Manager
Company Notices Section
ASX Limited
Rialto Towers
Level 45, 525 Collins Street
MELBOURNE VIC 3000

Dear Sir/Madam

Mayne Pharma Group Limited
Notice under ASX Listing Rule 3.10A

Mayne Pharma advises that pursuant to ASX Listing Rule 3.10A, the following securities which were subject to a 12-month voluntary escrow will be released from the holding lock on the following date:

Number of Securities	Description	Release date
85,772,626	Fully paid ordinary shares	16 May 2022

These already quoted shares were issued to Estetra SRL, a subsidiary of Mithra Pharmaceuticals, SA (**Mithra**). The shares were issued to Mithra as part of the consideration payable following FDA approval of NEXTSTELLIS® (E4/DSRP) oral contraceptive in the US.

This announcement has been authorised for release by the Company Secretary of Mayne Pharma.

Yours faithfully,
Mayne Pharma Group Limited



Laura Loftus
Company Secretary



Mayne Pharma Group Limited
ABN 76 115 832 963
maynepharma.com

T +61 8 8209 2666 F +61 8 8281 0284
1538 Main North Road, Salisbury South, SA 5106 Australia
PO Box 700, Salisbury, SA 5108 Australia